Multi-ScaleEvaluation and Mitigation of ToxicitiesFollowingInternalRadionuclideContamination
Project Number1P01AI165380-01
Contact PI/Project LeaderWOLOSCHAK, GAYLE E.
Awardee OrganizationNORTHWESTERN UNIVERSITY AT CHICAGO
Description
Abstract Text
OVERALL: ABSTRACT
History has taught us that exposures to radionuclides can happen any day almost anywhere in the US and
elsewhere and we have done little to prepare ourselves. Our ability to perform dosimetry modeling for such
scenarios and efforts into biomarker and mitigation discovery are archaic and our tendency to rely on external
beam radiation to model these is utterly misplaced. We should and we can do much better.
This program centers on the hypothesis that radiation from internal emitters is very unevenly distributed within a
body, amongst organs, and even within organs, tissues and cells. The half-life and decay schema of the
radionuclide, its activity and concentration, particle size and morphology, and its chemical form and solubility are
all critical, as are the route of uptake, tissue structure, genetic makeup, physiology, danger signaling and the
crosstalk with the immune system. Conceptually this suggests that the analysis of radionuclide distribution
requires measurements at the MESO, MICRO and NANO level for accurate dosimetry modeling and biokinetics
analyses, that will much better align with biological endpoints, and therefore with meaningful countermeasure
development. In many ways our program integrates the three main pillars of radiation science, namely radiation
physics, radiation chemistry and radiation biology, taking into account pharmacokinetics and pharmacodynamics
aspects of particle distribution at subcellular, cellular, and tissue levels.
In other words, to understand the biological effects of internal emitters and find the best possible mitigation
strategies a systematic study is called for, one that includes but is not limited to: a) radionuclide physical and
chemical form and intravital migration, b) protracted exposure times, c) radiation quality parameters, d) novel
virtual phantom modeling beyond few MACRO reference models ; e) novel biokinetics with sex- and age-
specificity; f) MESO, MICRO and NANO scale histology and immunohistochemistry with integrated radionuclide
distribution information; g) exploration of molecular biomarkers of radionuclide intake and contamination and h)
countermeasures that modulate radionuclide distribution and possibly also improve DNA, cell and tissue repair.
We have assembled a team with diverse scientific expertise that can tackle these challenges within an integrated
program. There is an incredibly impressive technological toolbox at our disposal and our goal is to generate a
meaningful blueprint for understanding and predicting biological consequences of exposure to radionuclides.
The possible benefits of this program to the radiation research community and the general population are
immense.
Public Health Relevance Statement
OVERALL: PROJECT NARRATIVE
Release of radionuclides after an industrial or medical radiological accident or detonation of a nuclear device
may result in significant radionuclide exposure of general population. This program entwines projects that
develop tools and approaches to evaluate, model and mitigate such exposures and their health threat.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
005436803
UEI
KG76WYENL5K1
Project Start Date
10-March-2022
Project End Date
28-February-2027
Budget Start Date
10-March-2022
Budget End Date
28-February-2023
Project Funding Information for 2022
Total Funding
$2,246,717
Direct Costs
$1,974,658
Indirect Costs
$272,059
Year
Funding IC
FY Total Cost by IC
2022
NIH Office of the Director
$2,246,717
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1P01AI165380-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1P01AI165380-01
Patents
No Patents information available for 1P01AI165380-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1P01AI165380-01
Clinical Studies
No Clinical Studies information available for 1P01AI165380-01
News and More
Related News Releases
No news release information available for 1P01AI165380-01
History
No Historical information available for 1P01AI165380-01
Similar Projects
No Similar Projects information available for 1P01AI165380-01